TY - JOUR
T1 - Therapeutic schedules influence the pattern of intellectual decline after irradiation of posterior fossa tumors
AU - Kieffer-Renaux, Virginie
AU - Viguier, Delphine
AU - Raquin, Marie Anne
AU - Laurent-Vannier, Anne
AU - Habrand, Jean Louis
AU - Dellatolas, Georges
AU - Kalifa, Chantal
AU - Hartmann, Olivier
AU - Grill, Jacques
PY - 2005/10/1
Y1 - 2005/10/1
N2 - Background. To evaluate intellectual decline in children with posterior fossa (PF) tumors treated with different therapeutic protocols. Procedure. Forty children had a complete neuropsychological evaluation prospectively twice, at least 6 months year (y) after the end of their treatment. Patients were classified into four groups according to treatment schedules: Group 1 (n = 7) PF radiotherapy (PFRT) alone at 50 Gy; Group 2 (n = 13) reduced-dose cranio-spinal irradiation (CSI) at 25 Gy with a PF boost; Group 3 (n = 9) standard CSI at 35 Gy and a PF boost; and Group 4 (n = 11) high-dose chemotherapy with stem cell support followed by PFRT at 50 Gy. Results. At the first evaluation (mean interval since diagnosis 3.7 y), the mean Full-Scale Intellectual Quotient (FSIQ) was 80 (SD = 19). Only patients in Group 1 had a normal mean IQ score of 92 (SD = 14). At the second evaluation (mean interval since diagnosis 6.3 y), the mean FSIQ scores were significantly lower with a mean difference of 2.4 points, i.e., a yearly decline of one point. The magnitude of the FSIQ decline was positively correlated with the first IQ score (P=0.0001) and inversely correlated with age at diagnosis (P=0.0005). A FSIQ decline was observed in all treatment groups except Group 1 (P=0.005). The differences in FSIQ observed initially between the four treatment groups persisted at the second evaluation. Conclusions. This study shows that FSIQ continues to decline more than 4 years after the diagnosis but this yearly decline seems to decrease with time from diagnosis. Therapeutic schedules influence the magnitude of this decline. Long-term follow-up into adulthood is necessary to effectively adapt patient rehabilitation.
AB - Background. To evaluate intellectual decline in children with posterior fossa (PF) tumors treated with different therapeutic protocols. Procedure. Forty children had a complete neuropsychological evaluation prospectively twice, at least 6 months year (y) after the end of their treatment. Patients were classified into four groups according to treatment schedules: Group 1 (n = 7) PF radiotherapy (PFRT) alone at 50 Gy; Group 2 (n = 13) reduced-dose cranio-spinal irradiation (CSI) at 25 Gy with a PF boost; Group 3 (n = 9) standard CSI at 35 Gy and a PF boost; and Group 4 (n = 11) high-dose chemotherapy with stem cell support followed by PFRT at 50 Gy. Results. At the first evaluation (mean interval since diagnosis 3.7 y), the mean Full-Scale Intellectual Quotient (FSIQ) was 80 (SD = 19). Only patients in Group 1 had a normal mean IQ score of 92 (SD = 14). At the second evaluation (mean interval since diagnosis 6.3 y), the mean FSIQ scores were significantly lower with a mean difference of 2.4 points, i.e., a yearly decline of one point. The magnitude of the FSIQ decline was positively correlated with the first IQ score (P=0.0001) and inversely correlated with age at diagnosis (P=0.0005). A FSIQ decline was observed in all treatment groups except Group 1 (P=0.005). The differences in FSIQ observed initially between the four treatment groups persisted at the second evaluation. Conclusions. This study shows that FSIQ continues to decline more than 4 years after the diagnosis but this yearly decline seems to decrease with time from diagnosis. Therapeutic schedules influence the magnitude of this decline. Long-term follow-up into adulthood is necessary to effectively adapt patient rehabilitation.
KW - Cerebellum
KW - Ependymoma
KW - Intellectual quotient
KW - Medulloblastoma
KW - Neuropsychological studies
KW - Therapeutic schedule
UR - http://www.scopus.com/inward/record.url?scp=26244446406&partnerID=8YFLogxK
U2 - 10.1002/pbc.20329
DO - 10.1002/pbc.20329
M3 - Article
C2 - 15924360
AN - SCOPUS:26244446406
SN - 1545-5009
VL - 45
SP - 814
EP - 819
JO - Pediatric Blood and Cancer
JF - Pediatric Blood and Cancer
IS - 6
ER -